Boehringer Ingelheim

FDA Approves Eli Lilly's and Boehringer Ingelheim Pharmaceuticals' Triple-Combination Diabetes Drug Trijardy XR
FDA Approves Eli Lilly's and Boehringer Ingelheim Pharmaceuticals' Triple-Combination Diabetes Drug Trijardy XR
Motley Fool
FDA
Eli Lilly
Boehringer Ingelheim
Trijardy XR
Jardiance
Tradjenta
metformin
diabetes
Flag link:
AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis
AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis
Motley Fool
AbbVie
Boehringer Ingelheim
Skyrizi
Novartis
Cosentyx
psoriasis
Flag link:
Boehringer Ingelheim inks 'Singapore's largest biotech deal,' promising $1B each for a suite of anti-fibrotic IL-11 drugs
Boehringer Ingelheim inks 'Singapore's largest biotech deal,' promising $1B each for a suite of anti-fibrotic IL-11 drugs
Endpoints
Boehringer Ingelheim
Singapore
fibrotic disease
Flag link:
Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese market
Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese market
Pharmaforum
Boehringer Ingelheim
China
BeiGene
drug manufacturing
Flag link:
As NASH shifts again, the focus remains on Genfit’s big readout
As NASH shifts again, the focus remains on Genfit’s big readout
EP Vantage
NASH
Genfit
elafibranor
Pfizer
Boehringer Ingelheim
Gilead Sciences
Poxel
Takeda
Intercept Pharma
Flag link:
Jardiance phase 3 exercise ability studies in chronic heart failure fail to meet primary endpoint
Jardiance phase 3 exercise ability studies in chronic heart failure fail to meet primary endpoint
Pharmaceutical Business Review
Jardiance
Eli Lilly
Boehringer Ingelheim
type 2 diabetes
chronic heart failure
clinical trials
Flag link:
Eli Lilly, Boehringer's Jardiance flops heart failure trial, falling behind AZ's Farxiga
Eli Lilly, Boehringer's Jardiance flops heart failure trial, falling behind AZ's Farxiga
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
Farxiga
diabetes
AstraZeneca
heart failure
Flag link:
AHA: Lilly, Boehringer's Jardiance cuts CV hospitalizations over rival diabetes meds
AHA: Lilly, Boehringer's Jardiance cuts CV hospitalizations over rival diabetes meds
Fierce Pharma
diabetes
AHA
heart failure
Eli Lilly
Boehringer Ingelheim
Jardiance
clinical trials
Flag link:
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
Zacks.com
Eli Lilly
Boehringer Ingelheim
FDA
Jardiance
type 1 diabetes
Flag link:
Boehringer, Eli Lilly begin sixth phase III study for Jardiance in heart failure
Boehringer, Eli Lilly begin sixth phase III study for Jardiance in heart failure
Pharmaceutical Business Review
Boehringer Ingelheim
Eli Lilly
Jardiance
heart failure
Flag link:
Lilly and Boehringer rejig diabetes alliance as Jardiance soars
Lilly and Boehringer rejig diabetes alliance as Jardiance soars
Pharmaforum
Eli Lilly
Boehringer Ingelheim
Jardiance
diabetes
type 2 diabetes
Flag link:
Which big pharma firms are best at digital?
Which big pharma firms are best at digital?
Pharmaforum
digital pharma
Bayer
Pfizer
Boehringer Ingelheim
Flag link:
Boehringer's VC wing backs anti-cancer virus startup
Boehringer's VC wing backs anti-cancer virus startup
Fierce Biotech
Abalos Therapeutics
arenavirus
Boehringer Ingelheim
cancer
Flag link:
As developers work on cracking KRAS, Germany's Boehringer has quietly begun testing its pan-KRAS drug in humans
As developers work on cracking KRAS, Germany's Boehringer has quietly begun testing its pan-KRAS drug in humans
Endpoints
KRAS
cancer
Boehringer Ingelheim
Flag link:
Boehringer Ingelheim's Ofev cuts rate of decline by 57% in range of rare lung diseases
Boehringer Ingelheim's Ofev cuts rate of decline by 57% in range of rare lung diseases
Fierce Pharma
Boehringer Ingelheim
Ofev
idiopathic pulmonary fibrosis
Flag link:
Boehringer Ingelheim signs retinal disease deal with Inflammasome
Boehringer Ingelheim signs retinal disease deal with Inflammasome
Pharmaceutical Business Review
Boehringer Ingelheim
Inflammasome Therapeutics
retinal disease
Flag link:
EASD: Lilly, BI tout new Jardiance kidney analysis as rival J&J nears FDA nod
EASD: Lilly, BI tout new Jardiance kidney analysis as rival J&J nears FDA nod
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
kidney disease
JNJ
EASD
Flag link:
ICER dings Novo's new oral diabetes drug
ICER dings Novo's new oral diabetes drug
Biopharma Dive
Novo Nordisk
diabetes
ICER
oral semaglutide
Eli Lilly
Boehringer Ingelheim
Jardiance
Ozempic
Flag link:
Boehringer Ingelheim’s Ofev secures FDA approval for SSc-ILD
Boehringer Ingelheim’s Ofev secures FDA approval for SSc-ILD
Pharmaceutical Business Review
Ofev
SSc-ILD
Boehringer Ingelheim
FDA
Flag link:
After inking a string of pipeline deals, Boehringer Ingelheim is doing a makeover of the top executive team
After inking a string of pipeline deals, Boehringer Ingelheim is doing a makeover of the top executive team
Endpoints
Boehringer Ingelheim
R&D
Flag link:

Pages